Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Pre-diabetic Patients
NCT05914857Phase 2Not yet recruiting
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in prediabetes, sponsored by Yungjin Pharm. Co., Ltd.. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05914857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914857.